Aberdeen Group plc Buys New Position in Kiniksa Pharmaceuticals International, plc $KNSA

Aberdeen Group plc bought a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 158,722 shares of the company’s stock, valued at approximately $6,163,000. Aberdeen Group plc owned 0.21% of Kiniksa Pharmaceuticals International at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of KNSA. Amundi acquired a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Kiniksa Pharmaceuticals International by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock worth $507,000 after acquiring an additional 1,002 shares in the last quarter. Millennium Management LLC grew its holdings in Kiniksa Pharmaceuticals International by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock worth $18,815,000 after purchasing an additional 67,452 shares during the period. Asset Management One Co. Ltd. increased its stake in Kiniksa Pharmaceuticals International by 624.2% in the second quarter. Asset Management One Co. Ltd. now owns 13,470 shares of the company’s stock valued at $373,000 after purchasing an additional 11,610 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Kiniksa Pharmaceuticals International during the second quarter valued at about $1,648,000. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals International Stock Performance

Kiniksa Pharmaceuticals International stock opened at $47.77 on Friday. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $18.25 and a fifty-two week high of $47.86. The firm’s 50-day simple moving average is $42.72 and its 200 day simple moving average is $39.37. The stock has a market cap of $3.62 billion, a PE ratio of 106.16 and a beta of 0.06.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. The Goldman Sachs Group raised their target price on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Wall Street Zen cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 2nd. Zacks Research lowered Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Finally, Wedbush lifted their price target on shares of Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the company an “outperform” rating in a research report on Tuesday, January 13th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $53.71.

Insider Activity at Kiniksa Pharmaceuticals International

In other news, COO Eben Tessari sold 12,048 shares of the firm’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $41.56, for a total transaction of $500,714.88. Following the completion of the sale, the chief operating officer directly owned 16,666 shares of the company’s stock, valued at $692,638.96. This trade represents a 41.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Mark Ragosa sold 17,845 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $43.28, for a total transaction of $772,331.60. Following the completion of the transaction, the chief financial officer directly owned 12,086 shares in the company, valued at $523,082.08. This trade represents a 59.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 123,823 shares of company stock valued at $5,244,967. 53.48% of the stock is owned by insiders.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.